Jan 24, 2023 7:00am EST Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
Jan 11, 2023 9:04am EST Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
Jan 10, 2023 7:00am EST Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow
Dec 28, 2022 7:00am EST Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer
Dec 08, 2022 7:00am EST Can-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis
Nov 25, 2022 7:00am EST Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update
Nov 02, 2022 7:15am EDT Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston
Oct 25, 2022 7:00am EDT Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®
Oct 13, 2022 7:00am EDT Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference
